Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) have been assigned an average recommendation of "Buy" from the six brokerages that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the last year is $132.67.

A number of research firms have recently weighed in on LNTH. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley dropped their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, Truist Financial dropped their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. The trade was a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC boosted its position in shares of Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after buying an additional 2,610,118 shares during the period. Farallon Capital Management LLC raised its holdings in Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after acquiring an additional 2,361,000 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in Lantheus by 2.2% during the first quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider's stock worth $155,101,000 after acquiring an additional 34,052 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after acquiring an additional 435,445 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Lantheus by 2.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider's stock worth $134,534,000 after acquiring an additional 31,454 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Down 1.2%

LNTH traded down $0.89 during trading on Monday, hitting $73.86. The company's stock had a trading volume of 671,503 shares, compared to its average volume of 988,498. The firm's 50 day moving average price is $94.56 and its two-hundred day moving average price is $92.08. Lantheus has a 12 month low of $73.11 and a 12 month high of $126.89. The stock has a market capitalization of $5.11 billion, a price-to-earnings ratio of 12.29 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.69 EPS. On average, sell-side analysts forecast that Lantheus will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.